Back to all papers

Leveraging AI for selective use of gadolinium contrast in brain MR.

July 30, 2026pubmed logopapers

Authors

Ingala S,Bauer M,Wamelink IIJHG,Perslev M,Sheng K,Birch Sørensen M,Llambias SN,Kothari A,Dwivedi E,Lillholm M,Barkhof F,Bachmann Nielsen M,Nielsen M,Jasperse BMMS,Keil VCW,Pai A

Affiliations (14)

  • Department of Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. [email protected].
  • Cerebriu A/S, Copenhagen, Denmark. [email protected].
  • Department of Radiology, Herlev and Gentofte University Hospital, Herlev, Denmark. [email protected].
  • Cerebriu A/S, Copenhagen, Denmark.
  • Department of Computer Science, University of Copenhagen, Copenhagen, Denmark.
  • Pioneer Centre for AI, Copenhagen, Denmark.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
  • Department of Brain Imaging, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Department of Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Applied Mathematics and Computer Science, Technical University of Denmark, Lyngby, Denmark.
  • Kothari Diagnostics Private Limited, Indore, India.
  • Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, UK.

Abstract

Gadolinium-based contrast agents used for brain magnetic resonance imaging improve lesion detection but are associated with acute side effects, concerns about long-term tissue deposition, and economic and environmental costs. Regulatory bodies and radiological societies therefore recommend minimizing their use where possible. This study aims to develop and evaluate a real-time artificial intelligence algorithm, Apollo SmartGAD, that optimizes imaging workflows by recommending contrast-enhanced, reduced-dose contrast-enhanced, or non-enhanced imaging protocols during acquisition. This retrospective, multicenter study evaluated 1251 adult magnetic resonance imaging examinations (mean age 52.1 ± 20.4 years; 577 females). Apollo SmartGAD analyzes images acquired during scanning and recommends non-enhanced, reduced-dose contrast-enhanced, or standard-dose contrast-enhanced imaging protocols. Performance was assessed in two distinct cohorts: patients undergoing first-time brain assessment and patients undergoing glioma monitoring. Here we show that, in the first-time brain assessment cohort, Apollo SmartGAD identifies examinations not requiring contrast administration with a sensitivity of 73%, a specificity of 79%, and a negative predictive value of 86%. In the glioma monitoring cohort, the algorithm differentiate between non-enhanced, reduced-dose contrast-enhanced, and standard-dose contrast-enhanced protocols with an overall sensitivity of 77% and a specificity of 78%. This study demonstrates that workflow-integrated, real-time artificial intelligence can support contrast administration decisions during brain magnetic resonance imaging. Such decision support may reduce unnecessary contrast use while preserving diagnostic performance, with potential benefits for patient safety, clinical efficiency, and sustainability.

Topics

Journal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.